Skip to Accessibility Tools Skip to Content Skip to Footer

Hepatitis C treatments Sovaldi and Harvoni will have exclusive coverage on CVS/Caremark

As of January 7, 2015, CVS/Caremark will have exclusive coverage for Gilead Sciences’ manufactured Hepatitis C treatments Sovaldi and Harvoni.1

Sovaldi was approved in December 2013 launched at $84,000 for 12 weeks of treatment. A combination of Sovaldi and another treatment, Harvoni, which is one daily pill, was approved in October 2014 launched at $94,500 for 12 weeks of treatment.1,2

Gilead has received criticism for its pricing and the US House Energy & Commerce Committee requested information on how cost was determined.2

In December, competitor AbbieVie’s Hepatitis C treatment Viekira Pak was approved by the FDA. Vierkira Pak, which is a combination of Viekira and Exviera, has exclusive coverage on Express Scripts and consists of several pills each day.1

In exchange for exclusive coverage, insurers may receive discounts for each of the treatments in 2015.

  1. Tirrell, M. Gilead fights back: CVS to cover its hepatitis C drugs exclusively. CNBC: 2015
  2. Barber, J. Gilead reveals deeper discounts in US for Sovaldi, Harvoni, above expectations. First Word Pharma: 2015